InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

- Current share price for NEU : $20.270

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,570 A$6.0 million Share placement & Share Purchase Plan 19 Sep 2006 10:03AM $0.420 $20.270 risen by 4,726.19%
$2,570 Half Yearly Report 12 Sep 2006 8:52AM $0.420 $20.270 risen by 4,726.19%
$2,570 Glypromate Phase 2 Trial with US Army 4 Sep 2006 9:47AM $0.430 $20.270 risen by 4,613.95%
$2,570 Glypromate Phase 2 trial final results 22 Aug 2006 8:29AM $0.465 $20.270 risen by 4,259.14%
$2,570 Neuren to present NNZ2566 Phase 2 Strategy 14 Aug 2006 8:31AM $0.430 $20.270 risen by 4,613.95%
$2,570 Selects candidate for oral treatment of Parkinsons 2 Aug 2006 8:29AM $0.450 $20.270 risen by 4,404.44%
$2,570 Commitments Test Entity - Second Quarter Report 31 Jul 2006 3:48PM $0.500 $20.270 risen by 3,954%
$2,570 Further US Army results presented on NNZ-2566 29 May 2006 9:57AM $0.510 $20.270 risen by 3,874.51%
$2,570 Granted US patent for NNZ-2566 11 May 2006 11:48AM $0.550 $20.270 risen by 3,585.45%
$2,570 Commitments Test Entity - First Quarter Report 28 Apr 2006 1:25PM $0.575 $20.270 risen by 3,425.22%
$2,570 Neuren & US Army NNZ 2566 brain seizure results 26 Apr 2006 8:30AM $0.585 $20.270 risen by 3,364.96%
$2,570 Reports successful Phase 2 results 12 Apr 2006 9:02AM $0.605 $20.270 risen by 3,250.41%
$2,570 Preclinical results for oral administration of NNZ-2566 22 Mar 2006 8:45AM $0.590 $20.270 risen by 3,335.59%
$2,570 NNZ-2566 Phase 1 trial to commence 6 Mar 2006 8:31AM $0.570 $20.270 risen by 3,456.14%
$2,570 Preliminary Final Report 28 Feb 2006 9:05AM $0.570 $20.270 risen by 3,456.14%
$2,570 FDA pre-clinical requirements to Phase 3 completed 1 Feb 2006 11:07AM $0.530 $20.270 risen by 3,724.53%
$2,570 Commitments Test Entity - Fourth Quarter Report 31 Jan 2006 3:12PM $0.530 $20.270 risen by 3,724.53%
$2,570 Short Form Prospectus 2 Dec 2005 10:14AM n/a $20.270 n/a
$2,570 Neuren raises $6.4 million in share placement 2 Dec 2005 8:54AM n/a $20.270 n/a
$2,570 Reinstatement to Official Quotation 2 Dec 2005 8:53AM n/a $20.270 n/a
$2,570 Suspension from Official Quotation 1 Dec 2005 8:48AM n/a $20.270 n/a
$2,570 Trading Halt 29 Nov 2005 9:02AM n/a $20.270 n/a
$2,570 Neuren Agreement with Jackson Foundation for Phase 3 24 Nov 2005 9:15AM $0.630 $20.270 risen by 3,117.46%
$2,570 Commitments Test Entity - Third Quarter Report 31 Oct 2005 2:41PM $0.690 $20.270 risen by 2,837.68%
$2,570 Response to ASX Share Price Query 3 Oct 2005 8:41AM $0.500 $20.270 risen by 3,954%

801 - 825 of 833 results

Page 33 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.